Product Overview
Structure
Active substance:
Sodium methylthionitrooxodihydrotriazolotriazinide dihydrate (triazavirin) - 250 mg.
Excipients:
Calcium stearate - 2 mg;
The mass of the contents of the capsule is 252 mg;
The composition of the capsule shell:
Capsule (case) No. 1: titanium dioxide (E171), yellow quinoline (E104), yellow "sunset" (E110), medical gelatin.
Capsule (cap) No. 1: titanium dioxide (E171), azorubine (E122), medical gelatin.
pharmachologic effect
Pharmacodynamics:
The active substance of the drug is a synthetic analogue of the bases of purine nucleosides (guanine) with a pronounced antiviral effect. It has a wide range of antiviral activity against RNA viruses.
The main mechanism of action of the drug is inhibition of viral RNA synthesis and replication of genomic fragments.
Pharmacokinetics:
After oral administration, it is rapidly absorbed in the digestive tract. The maximum concentration (C is the x) is reached after an average of 1-1.5 hours. With minute at the recommended dosing regimen is an average of 4.8 ug / ml. The blood AUC is 12.8 μg / h * ml. The half-life (Ti / 2 ) is 1-1.5 hours.
From 15 to 45% of the drug is excreted unchanged by the kidneys. The average value of the estimated clearance is 246 ml / min.
Indications
Flu treatment in adults. If necessary, the drug should be combined with the administration of symptomatic agents.
Contraindications
-
hypersensitivity to the components of the drug;
-
pregnancy;
-
the period of breastfeeding;
-
children under 18 years of age (efficacy and safety not determined);
-
renal failure (efficacy and safety not determined).
-
liver failure (efficacy and safety not determined)
Side effects
-
allergic reactions;
-
dyspeptic disorders (flatulence, diarrhea, nausea, vomiting).
If side effects worsen, or you notice any other side effects not listed in the instructions, you should inform your doctor.
Interaction
Interaction with analogues of purine and pyrimidine bases during antitumor therapy can increase the toxicity of the drug. With simultaneous use with ribavirin, a dose reduction of ribavirin is required.
How to take, course of administration and dosage
Triazavirin® is administered orally regardless of food intake.
The drug should be started no later than the 2nd day from the onset of the disease (onset of clinical symptoms), 1 capsule (250 mg) 3 times a day (daily dose - 750 mg) for 5 days. If necessary, treatment can be continued up to 7 days.
Overdose
Symptoms: nausea, vomiting, dyspeptic disorders, stomach pain.
Treatment: symptomatic therapy. If these symptoms appear, stop taking the drug.
Release form
Capsules
